Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB5 versus Humira in moderate to severe rheumatoid arthritis despite methotrexate therapy
2013-005013-13Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Samsung Bioepis. Primary endpoint: ACR20 response at Week 24. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-005013-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005013-13.